WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202570
Description: Satraplatin, also known as JM216 and BMS182751, is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.
MedKoo Cat#: 202570
Chemical Formula: C10H22Cl2N2O4Pt
Exact Mass: 499.06044
Molecular Weight: 500.28
Elemental Analysis: C, 24.01; H, 4.43; Cl, 14.17; N, 5.60; O, 12.79; Pt, 38.99
Synonym: BMS182751; BMS 182751; BMS-182751; JM 216; JM-216; JM216; Satraplatin
IUPAC/Chemical Name: (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum
InChi Key: CKNPWBAXEKSCRG-UHFFFAOYSA-J
InChi Code: InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+4/p-4
SMILES Code: CC(O[Pt]([NH2]C1CCCCC1)(Cl)(Cl)([NH3])OC(C)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not soluble in water.
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 500.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Doshi G, Sonpavde G, Sternberg CN. Clinical and pharmacokinetic evaluation of satraplatin. Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):103-11. doi: 10.1517/17425255.2012.636352. Epub 2011 Nov 19. Review. PubMed PMID: 22098065.
2: Bhargava A, Vaishampayan UN. Satraplatin: leading the new generation of oral platinum agents. Expert Opin Investig Drugs. 2009 Nov;18(11):1787-97. doi: 10.1517/13543780903362437. Review. PubMed PMID: 19888874.
3: Sonpavde G, Sternberg CN. Satraplatin for the therapy of castration-resistant prostate cancer. Future Oncol. 2009 Sep;5(7):931-40. doi: 10.2217/fon.09.84. Review. PubMed PMID: 19792961.
4: Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res. 2008 Mar 15;14(6):1633-8. doi: 10.1158/1078-0432.CCR-07-2176. Review. PubMed PMID: 18347164.
5: Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. Expert Opin Investig Drugs. 2007 Jul;16(7):1009-21. Review. PubMed PMID: 17594186.
6: McKeage MJ. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation. Drugs. 2007;67(6):859-69. Review. PubMed PMID: 17428104.
7: Satraplatin: BMS 182751, BMY 45594, JM 216. Drugs R D. 2007;8(2):125-32. Review. PubMed PMID: 17324011.
8: Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther. 2006 Jul;6(7):973-82. Review. PubMed PMID: 16831070.
9: Satraplatin. BMS 182751, BMY 45594, JM 216. Drugs R D. 2002;3(1):67-71. Review. PubMed PMID: 11881537.
10: Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs. 2000 Jun;9(6):1373-82. Review. PubMed PMID: 11060749.
According to news published in 8 Jul 2008, GPC Biotech AG reported that the Company has been informed by its partner for satraplatin in Europe that they plan to withdraw the Marketing Authorization Application (MAA) for satraplatin plus prednisone for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed. This decision was based on a list of outstanding issues received following review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) of the filing, which indicates that the opinion of the Committee is that the application is currently not approvable based on the information provided. see: http://www.medicalnewstoday.com/articles/116301.php .